Clinical Trial Update: RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study (RaPiDS) evaluating anti-PD-1 alone or with an anti-CTLA-4 in second-line cervical cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Anti-PD-1 therapy
• anti-CTLA-4 therapy (CTLA-4 inhibitor)

Snippet

Sponsor: Agenus Inc. | Conditions: Cervical Cancer | Phase 2 | Status: TERMINATED